Clinical Trial

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

Study acronym: SELECT
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase II, two-arm, single center, patient preference study designed to evaluate the impact of omitting adjuvant chemotherapy in moderate to high-anatomical risk, low-genomic risk (men or premenopausal women T2-3N0 and RS 16-25, or T1-3N1-2 and RS ≤ 25, and postmenopausal women T2-3N0 and RS 26-30, or T1-3N1 and RS 26-30, or T1-3N2 and RS ≤ 25),
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-04-29; most recent amendment 2026-05-20.
Status change: Not Yet Recruiting → Recruiting 2025-07-10
Trial Details
NCT Number NCT06953882
Lead Sponsor Yale University
Collaborators: Novartis, Breast Cancer Research Foundation
Conditions HER2 Negative Breast Cancer
Enrollment 140 participants
Start Date 2025-07-09
Primary Completion 2030-09 (estimated)
Study Completion 2030-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-26